{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:39:04Z","timestamp":1771382344058,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00392-021-01962-4","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T07:02:52Z","timestamp":1636527772000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT"],"prefix":"10.1007","volume":"111","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[]},{"given":"Marc","family":"Pfeffer","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"issue":"15","key":"1962_CR1","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","volume":"137","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation 137(15):1614\u20131631","journal-title":"Circulation"},{"issue":"2","key":"1962_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pcad.2018.05.005","volume":"61","author":"TB Horwich","year":"2018","unstructured":"Horwich TB, Fonarow GC, Clark AL (2018) Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 61(2):151\u2013156","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"1962_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10741-018-09766-x","volume":"24","author":"M Tadic","year":"2019","unstructured":"Tadic M, Cuspidi C (2019) Obesity and heart failure with preserved ejection fraction: a paradox or something else? Heart Fail Rev 24(3):379\u2013385","journal-title":"Heart Fail Rev"},{"issue":"2","key":"1962_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00392-018-1302-7","volume":"108","author":"J Zhang","year":"2019","unstructured":"Zhang J, Begley A, Jackson R, Harrison M, Pellicori P, Clark AL, Cleland JGF (2019) Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis. Clin Res Cardiol 108(2):119\u2013132","journal-title":"Clin Res Cardiol"},{"issue":"21","key":"1962_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2008.12.068","volume":"53","author":"CJ Lavie","year":"2009","unstructured":"Lavie CJ, Milani RV, Ventura HO (2009) Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53(21):1925\u20131932","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1962_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ejhf.240","volume":"17","author":"P Rossignol","year":"2015","unstructured":"Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R (2015) Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail 17(4):424\u2013433","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"1962_CR7","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/eurheartj\/ehn420","volume":"29","author":"SJ Pocock","year":"2008","unstructured":"Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB (2008) Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 29(21):2641\u20132650","journal-title":"Eur Heart J"},{"issue":"28","key":"1962_CR8","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1093\/eurheartj\/ehaa069","volume":"41","author":"O Moussa","year":"2020","unstructured":"Moussa O, Ardissino M, Heaton T, Tang A, Khan O, Ziprin P, Darzi A, Collins P, Purkayastha S (2020) Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J 41(28):2660\u20132667","journal-title":"Eur Heart J"},{"issue":"26","key":"1962_CR9","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/eurheartj\/ehz295","volume":"40","author":"S Jamaly","year":"2019","unstructured":"Jamaly S, Carlsson L, Peltonen M, Jacobson P, Karason K (2019) Surgical obesity treatment and the risk of heart failure. Eur Heart J 40(26):2131\u20132138","journal-title":"Eur Heart J"},{"issue":"2","key":"1962_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000910","volume":"5","author":"S Berger","year":"2018","unstructured":"Berger S, Meyre P, Blum S, Aeschbacher S, Ruegg M, Briel M, Conen D (2018) Bariatric surgery among patients with heart failure: a systematic review and meta-analysis. Open Heart 5(2):e000910","journal-title":"Open Heart"},{"issue":"1","key":"1962_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ehf2.12370","volume":"6","author":"J Howie-Esquivel","year":"2019","unstructured":"Howie-Esquivel J, Dracup K, Whooley MA, McCulloch C, Jin C, Moser DK, Clark RA, Pelter MM, Biddle M, Park LG (2019) Rapid 5 lb weight gain is not associated with readmission in patients with heart failure. ESC Heart Fail 6(1):131\u2013137","journal-title":"ESC Heart Fail"},{"issue":"9","key":"1962_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ejhf.792","volume":"19","author":"A Olivier","year":"2017","unstructured":"Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJV, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A (2017) Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Eur J Heart Fail 19(9):1186\u20131197","journal-title":"Eur J Heart Fail"},{"key":"1962_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","volume":"146","author":"K Elkholey","year":"2021","unstructured":"Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S (2021) Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol 146:36\u201347","journal-title":"Am J Cardiol"},{"issue":"6","key":"1962_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","volume":"162","author":"AS Desai","year":"2011","unstructured":"Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O\u2019Meara E, Shaburishvili T, Pitt B, Pfeffer MA (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162(6):966-972.e10","journal-title":"Am Heart J"},{"issue":"15","key":"1962_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O\u2019Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"1","key":"1962_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O\u2019Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34\u201342","journal-title":"Circulation"},{"issue":"17","key":"1962_CR17","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL (2017) Spironolactone metabolites in TOPCAT\u2014new insights into regional variation. N Engl J Med 376(17):1690\u20131692","journal-title":"N Engl J Med"},{"issue":"19","key":"1962_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1161\/01.CIR.102.19.2325","volume":"102","author":"J Bauersachs","year":"2000","unstructured":"Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M (2000) Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 102(19):2325\u20132328","journal-title":"Circulation"},{"issue":"6","key":"1962_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2020","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, Gonz\u00e1lez A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F (2020) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u201cOMics\u201d in AGEing (HOMAGE) randomized clinical trial. Eur Heart J 42(6):684\u2013696","journal-title":"Eur Heart J"},{"issue":"4","key":"1962_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","volume":"5","author":"IS Anand","year":"2017","unstructured":"Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O\u2019Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD (2017) Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail 5(4):241\u2013252","journal-title":"JACC Heart Fail"},{"key":"1962_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","volume":"4","author":"IS Anand","year":"2011","unstructured":"Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail USA 4:569\u2013577","journal-title":"Circ Heart Fail USA"},{"issue":"4","key":"1962_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11897-013-0153-9","volume":"10","author":"V Pureza","year":"2013","unstructured":"Pureza V, Florea VG (2013) Mechanisms for cachexia in heart failure. Curr Heart Fail Rep 10(4):307\u2013314","journal-title":"Curr Heart Fail Rep"},{"issue":"9","key":"1962_CR23","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/ejhf.1909","volume":"22","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Rossello X, Pocock SJ, Rossignol P, Claggett BL, Rouleau JL, Solomon SD, Pitt B, Pfeffer MA, Zannad F (2020) Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. Eur J Heart Fail 22(9):1615\u20131624","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01962-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01962-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01962-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:12:39Z","timestamp":1648717959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01962-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1962"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01962-4","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflicts of interest to report regarding the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}